Cargando…

Chinese patent herbal medicine (Shufeng Jiedu capsule) for acute upper respiratory tract infections: A systematic review and meta-analysis

Background: Shufeng Jiedu capsule has been widely used in China for acute upper respiratory tract infections (AURTIs). The aim of this study was to evaluate its effectiveness and safety for AURTIs. Methods: Randomized controlled trials comparing SFJD with conventional drug for patients with AURTIs w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ying-ying, Xia, Ru-yu, Liang, Shi-bing, Hu, Xiao-yang, Dai, Meng-yuan, Li, Yi-lin, Zhao, Le-yi, Moore, Michael, Fei, Yu-tong, Liu, Jian-ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099504/
https://www.ncbi.nlm.nih.gov/pubmed/33996460
http://dx.doi.org/10.1016/j.imr.2021.100726
_version_ 1783688583237861376
author Zhang, Ying-ying
Xia, Ru-yu
Liang, Shi-bing
Hu, Xiao-yang
Dai, Meng-yuan
Li, Yi-lin
Zhao, Le-yi
Moore, Michael
Fei, Yu-tong
Liu, Jian-ping
author_facet Zhang, Ying-ying
Xia, Ru-yu
Liang, Shi-bing
Hu, Xiao-yang
Dai, Meng-yuan
Li, Yi-lin
Zhao, Le-yi
Moore, Michael
Fei, Yu-tong
Liu, Jian-ping
author_sort Zhang, Ying-ying
collection PubMed
description Background: Shufeng Jiedu capsule has been widely used in China for acute upper respiratory tract infections (AURTIs). The aim of this study was to evaluate its effectiveness and safety for AURTIs. Methods: Randomized controlled trials comparing SFJD with conventional drug for patients with AURTIs were included. Eight databases were searched from their inceptions to February 2021. Data was synthesized using risk ration (RR) or mean difference (MD) with their 95% confidence interval (CI). The primary outcome was resolution time of typical symptoms. Results: Twenty-five RCTs involving 3410 patients were included. SFJD in combination with conventional drug was associated with; in common cold shortening the duration of fever (MD −1.54 days, 95% CI [−2.15,−0.92], I(2) = 80%, n = 385, 3 trials) and cough (MD −1.22 days, 95% CI [−1.52, −0.93]); in herpangina, shortening the duration of fever (MD -0.68 days, 95% CI [−1.15, −0.21], I(2) = 68%, n = 140, 2 trials) and blistering (MD −0.99 days, 95% CI [−1.23, −0.76], n = 386, 3 trials); in acute tonsillitis and acute pharyngitis shortening the duration of fever (MD −1.13 days, 95% CI [−1.36, −0.90], I(2) = 33%, n = 688, 7 trials) and sore throat (MD −1.13 days, 95% CI [−1.40, −0.86], I(2) = 84.1%, n = 1194, 10 trials). SFJD also improving their cure rate with a range (1–5 days). No serious adverse events were reported. Conclusion: Low certainty evidence suggests that SFJD appears to shorten the duration of symptoms in AURTIs, improve cure rate and seems safe for application. However, high quality placebo controlled trials are warranted to confirm its benefit.
format Online
Article
Text
id pubmed-8099504
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-80995042021-05-13 Chinese patent herbal medicine (Shufeng Jiedu capsule) for acute upper respiratory tract infections: A systematic review and meta-analysis Zhang, Ying-ying Xia, Ru-yu Liang, Shi-bing Hu, Xiao-yang Dai, Meng-yuan Li, Yi-lin Zhao, Le-yi Moore, Michael Fei, Yu-tong Liu, Jian-ping Integr Med Res Original Article Background: Shufeng Jiedu capsule has been widely used in China for acute upper respiratory tract infections (AURTIs). The aim of this study was to evaluate its effectiveness and safety for AURTIs. Methods: Randomized controlled trials comparing SFJD with conventional drug for patients with AURTIs were included. Eight databases were searched from their inceptions to February 2021. Data was synthesized using risk ration (RR) or mean difference (MD) with their 95% confidence interval (CI). The primary outcome was resolution time of typical symptoms. Results: Twenty-five RCTs involving 3410 patients were included. SFJD in combination with conventional drug was associated with; in common cold shortening the duration of fever (MD −1.54 days, 95% CI [−2.15,−0.92], I(2) = 80%, n = 385, 3 trials) and cough (MD −1.22 days, 95% CI [−1.52, −0.93]); in herpangina, shortening the duration of fever (MD -0.68 days, 95% CI [−1.15, −0.21], I(2) = 68%, n = 140, 2 trials) and blistering (MD −0.99 days, 95% CI [−1.23, −0.76], n = 386, 3 trials); in acute tonsillitis and acute pharyngitis shortening the duration of fever (MD −1.13 days, 95% CI [−1.36, −0.90], I(2) = 33%, n = 688, 7 trials) and sore throat (MD −1.13 days, 95% CI [−1.40, −0.86], I(2) = 84.1%, n = 1194, 10 trials). SFJD also improving their cure rate with a range (1–5 days). No serious adverse events were reported. Conclusion: Low certainty evidence suggests that SFJD appears to shorten the duration of symptoms in AURTIs, improve cure rate and seems safe for application. However, high quality placebo controlled trials are warranted to confirm its benefit. Elsevier 2021-09 2021-04-02 /pmc/articles/PMC8099504/ /pubmed/33996460 http://dx.doi.org/10.1016/j.imr.2021.100726 Text en © 2021 Published by Elsevier B.V. on behalf of Korea Institute of Oriental Medicine. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Zhang, Ying-ying
Xia, Ru-yu
Liang, Shi-bing
Hu, Xiao-yang
Dai, Meng-yuan
Li, Yi-lin
Zhao, Le-yi
Moore, Michael
Fei, Yu-tong
Liu, Jian-ping
Chinese patent herbal medicine (Shufeng Jiedu capsule) for acute upper respiratory tract infections: A systematic review and meta-analysis
title Chinese patent herbal medicine (Shufeng Jiedu capsule) for acute upper respiratory tract infections: A systematic review and meta-analysis
title_full Chinese patent herbal medicine (Shufeng Jiedu capsule) for acute upper respiratory tract infections: A systematic review and meta-analysis
title_fullStr Chinese patent herbal medicine (Shufeng Jiedu capsule) for acute upper respiratory tract infections: A systematic review and meta-analysis
title_full_unstemmed Chinese patent herbal medicine (Shufeng Jiedu capsule) for acute upper respiratory tract infections: A systematic review and meta-analysis
title_short Chinese patent herbal medicine (Shufeng Jiedu capsule) for acute upper respiratory tract infections: A systematic review and meta-analysis
title_sort chinese patent herbal medicine (shufeng jiedu capsule) for acute upper respiratory tract infections: a systematic review and meta-analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099504/
https://www.ncbi.nlm.nih.gov/pubmed/33996460
http://dx.doi.org/10.1016/j.imr.2021.100726
work_keys_str_mv AT zhangyingying chinesepatentherbalmedicineshufengjieducapsuleforacuteupperrespiratorytractinfectionsasystematicreviewandmetaanalysis
AT xiaruyu chinesepatentherbalmedicineshufengjieducapsuleforacuteupperrespiratorytractinfectionsasystematicreviewandmetaanalysis
AT liangshibing chinesepatentherbalmedicineshufengjieducapsuleforacuteupperrespiratorytractinfectionsasystematicreviewandmetaanalysis
AT huxiaoyang chinesepatentherbalmedicineshufengjieducapsuleforacuteupperrespiratorytractinfectionsasystematicreviewandmetaanalysis
AT daimengyuan chinesepatentherbalmedicineshufengjieducapsuleforacuteupperrespiratorytractinfectionsasystematicreviewandmetaanalysis
AT liyilin chinesepatentherbalmedicineshufengjieducapsuleforacuteupperrespiratorytractinfectionsasystematicreviewandmetaanalysis
AT zhaoleyi chinesepatentherbalmedicineshufengjieducapsuleforacuteupperrespiratorytractinfectionsasystematicreviewandmetaanalysis
AT mooremichael chinesepatentherbalmedicineshufengjieducapsuleforacuteupperrespiratorytractinfectionsasystematicreviewandmetaanalysis
AT feiyutong chinesepatentherbalmedicineshufengjieducapsuleforacuteupperrespiratorytractinfectionsasystematicreviewandmetaanalysis
AT liujianping chinesepatentherbalmedicineshufengjieducapsuleforacuteupperrespiratorytractinfectionsasystematicreviewandmetaanalysis